1. Home
  2. ERAS vs OCFC Comparison

ERAS vs OCFC Comparison

Compare ERAS & OCFC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ERAS
  • OCFC
  • Stock Information
  • Founded
  • ERAS 2018
  • OCFC 1902
  • Country
  • ERAS United States
  • OCFC United States
  • Employees
  • ERAS N/A
  • OCFC N/A
  • Industry
  • ERAS Biotechnology: Pharmaceutical Preparations
  • OCFC Major Banks
  • Sector
  • ERAS Health Care
  • OCFC Finance
  • Exchange
  • ERAS Nasdaq
  • OCFC Nasdaq
  • Market Cap
  • ERAS 719.0M
  • OCFC 1.1B
  • IPO Year
  • ERAS 2021
  • OCFC 1996
  • Fundamental
  • Price
  • ERAS $3.14
  • OCFC $20.16
  • Analyst Decision
  • ERAS Strong Buy
  • OCFC Hold
  • Analyst Count
  • ERAS 5
  • OCFC 3
  • Target Price
  • ERAS $6.10
  • OCFC $19.33
  • AVG Volume (30 Days)
  • ERAS 1.6M
  • OCFC 261.0K
  • Earning Date
  • ERAS 11-15-2024
  • OCFC 10-17-2024
  • Dividend Yield
  • ERAS N/A
  • OCFC 3.97%
  • EPS Growth
  • ERAS N/A
  • OCFC N/A
  • EPS
  • ERAS N/A
  • OCFC 1.74
  • Revenue
  • ERAS N/A
  • OCFC $380,971,000.00
  • Revenue This Year
  • ERAS N/A
  • OCFC N/A
  • Revenue Next Year
  • ERAS N/A
  • OCFC $4.30
  • P/E Ratio
  • ERAS N/A
  • OCFC $11.58
  • Revenue Growth
  • ERAS N/A
  • OCFC N/A
  • 52 Week Low
  • ERAS $1.51
  • OCFC $12.93
  • 52 Week High
  • ERAS $3.45
  • OCFC $21.21
  • Technical
  • Relative Strength Index (RSI)
  • ERAS 63.60
  • OCFC 62.61
  • Support Level
  • ERAS $2.59
  • OCFC $17.57
  • Resistance Level
  • ERAS $3.31
  • OCFC $21.21
  • Average True Range (ATR)
  • ERAS 0.20
  • OCFC 0.63
  • MACD
  • ERAS 0.06
  • OCFC 0.21
  • Stochastic Oscillator
  • ERAS 80.92
  • OCFC 71.31

About ERAS Erasca Inc.

Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.

About OCFC OceanFirst Financial Corp.

OceanFirst Financial Corp is engaged in the banking sector of the United States. It conducts the business of attracting retail and business deposits and investing them in loans, consisting of single-family, owner-occupied residential mortgage loans, and commercial real estate loans. The company's sole segment deals with the delivery of loan and deposit products to customers. The bank's revenues are derived principally from interest on its loans, and to a lesser extent, interest on its investment and mortgage-backed securities. The rest of its income is dependent on bank card services and wealth management services.

Share on Social Networks: